HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $462 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $462.
May 07, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals maintains a Buy rating and a $462 price target from HC Wainwright & Co.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in the stock's price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100